ライフサイエンスコーパス: anticonvulsants

1 -benzyl-2-acetamidoacetamides (2) are potent anticonvulsants.

2 tics, class I antiarrhythmic drugs, and some anticonvulsants.

3 ccupied by traditional local anesthetics and anticonvulsants.

4 nce seizure generation and responsiveness to anticonvulsants.

5 acting drugs, including antidepressants and anticonvulsants.

6 t spontaneous convulsions (>1 per hour) with anticonvulsants.

7 g-sensitive (BS) mutants as a tool to screen anticonvulsants.

8 by hypoxia can be refractory to conventional anticonvulsants.

9 logical conditions and is the target of some anticonvulsants.

10 Its pharmacology seems unaffected by anticonvulsants.

11 40 (5.6%) of 716 patients received anticonvulsants.

12 (p=0.26) was found among patients receiving anticonvulsants.

13 lopmental quotient (DQ) > 30 did not require anticonvulsants.

14 ng effects on block by local anesthetics and anticonvulsants.

15 SSRIs and SNRIs; -0.91, -1.23 to -0.60), and anticonvulsants (-0.81, -1.36 to -0.28).

16 The potent anticonvulsants 83a and 83j had greatly diminished carbo

17 to the hypothesis that lithium and antimanic anticonvulsants act by targeting parts of the "arachidon

18 Adults not taking enzyme-inducing anticonvulsants after resection or biopsy of GBM were tr

19 i); and Bn, Et (7j)] are also very effective anticonvulsants against seizures induced by maximal elec

20 psychotropic classes (e.g., antidepressants, anticonvulsants), although they may be safer options.

21 ues in patients treated with enzyme-inducing anticonvulsants, although this did not reach statistical

22 The sensitivity to anticonvulsants and anesthetics of Ca(2+) currents arisi

23 Evidence supports the use of specific anticonvulsants and antidepressants for pain management

24 ly important compounds, including diuretics, anticonvulsants and antidepressants, many of which have

25 ation suggest that concurrent treatment with anticonvulsants and dexamethasone enhances drug clearanc

26 er combinations appear to be the mixtures of anticonvulsants and lithium, particularly valproate plus

27 sts that could have therapeutic potential as anticonvulsants and neuroprotectants.

28 drugs with a focus on the controlled use of anticonvulsants and steroids.

29 ceptor are important anesthetics, sedatives, anticonvulsants, and anxiolytics.

30 es occur frequently, are often refractory to anticonvulsants, and are associated with considerable mo

31 Clinicians should utilize omega-3, anticonvulsants, and atypical antipsychotic agents in tr

32 low-potency phenothiazines, lithium, certain anticonvulsants, and benzodiazepines may increase the re

33 mptomatic treatment with corticosteroids and anticonvulsants, and definitive therapy in the form of w

34 inhibitors, cinchona alkaloids, antibiotics, anticonvulsants, and heparin.

35 Phenylalanine, teratogenic anticonvulsants, and high concentrations of glucose did

36 t is potentiated by widely used anxiolytics, anticonvulsants, and hypnotics.

37 neurological symptoms, with gabapentin-type anticonvulsants, and is among the first in nonepileptic

38 hotics for schizophrenia and antipsychotics, anticonvulsants, and lithium for bipolar disorder.

39 Antiarrhythmics, anticonvulsants, and local anesthetics target voltage-ga

40 r-bipolar subtype (N = 15) for whom lithium, anticonvulsants, and neuroleptics had been ineffective,

41 Barbiturates are widely used as anesthetics, anticonvulsants, and neuroprotective agents.

42 reatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity

43 Their therapeutic potential as anxiolytics, anticonvulsants, and sedative/hypnotics is limited by ra

44 utic drugs and supportive-care drugs-such as anticonvulsants, antiemetics, uric-acid-lowering compoun

45 esthetics, antiarrhythmics, antidepressants, anticonvulsants, antihistamines, antihypertensives, anti

46 17-3.81; P for trend < .001), whereas use of anticonvulsants, antipsychotics, or antidepressants was

47 ulate GABAA receptors have potential uses as anticonvulsants, anxiolytics, and sedative-hypnotic agen

48 Therefore, new and more effective anticonvulsants are continually sought after to combat t

49 These anticonvulsants are neutral, in contrast to the mostly p

50 Broad-spectrum anticonvulsants are of considerable interest as antiepil

51 Maintenance treatment with lithium or anticonvulsants as practiced in modern care is associate

52 PURPOSE OF REVIEW: Despite myriad anticonvulsants available and in various stages of devel

53 s to specific treatments, including sedative anticonvulsants (barbiturates and benzodiazepines) and E

54 ney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids.

55 de: antidepressants, anti-adrenergic agents, anticonvulsants, benzodiazepines, atypical antipsychotic

56 dditional commonly used Na(+) channel-acting anticonvulsants, both in control and epileptic animals.

57 ies and other risk factors, among individual anticonvulsants compared with topiramate and secondarily

58 We investigated whether anticonvulsants compromise the efficacy of cancer chemot

59 .80-3.42; P for trend < .001), as was use of anticonvulsants (definite CKD, 1-2 prescriptions: HR = 1

60 unds represent novel leads in the search for anticonvulsants devoid of sedative, ataxic, and amnestic

61 zyl-3-ethyl lactam 7j are the most effective anticonvulsants (ED50 = 46 and 42 mg/kg, respectively) a

62 d in patients receiving p450 enzyme-inducing anticonvulsants (EIACs) by 73%, 47%, and 50%, respective

63 aging or EEG), prophylactic antipyretics and anticonvulsants far outweigh their potential benefits.

64 sia and eclampsia; and short-term parenteral anticonvulsants for seizures associated with encephalopa

65 Although anticonvulsants have proven very helpful in treating sei

66 ll have surprisingly high in vivo potency as anticonvulsants in a mouse maximal electroshock-induced

67 ncy O-methylated analogue 18 are both potent anticonvulsants in a mouse maximal electroshock-induced

68 ) derivatives were prepared and evaluated as anticonvulsants in mice.

69 in are equally but incompletely effective as anticonvulsants in neonates.

70 ge underlying precipitant causes, administer anticonvulsants in rapid succession until seizures have

71 ation, and for prophylactic antipyretics and anticonvulsants, in the majority of children with simple

72 Lithium and certain anticonvulsants, including carbamazepine and valproic ac

73 the most teratogenic of commonly prescribed anticonvulsants, increasing the risk in humans of major

74 ds, acetaminophen, anti-inflammatory agents, anticonvulsants, ketamine, clonidine, mexiletine, antide

75 o change treatment to one of the noninducing anticonvulsants lamotrigine or levetiracetam.

76 re antidepressants, atypical antipsychotics, anticonvulsants, lithium, and other medications used in

77 ior, in addition to concerns that the use of anticonvulsants may increase self-harm.

78 ts exposed to either lithium (n = 26,731) or anticonvulsants (n=420,959).

79 Some drugs developed as anticonvulsants (notably, valproate and lamotrigine) hav

80 sed to assess the prognostic significance of anticonvulsants on event-free survival and risk of haema

81 ds for chronic noncancer pain, compared with anticonvulsants or cyclic antidepressants, was associate

82 for long-acting opioids or either analgesic anticonvulsants or low-dose cyclic antidepressants (cont

83 ) or were nonambulatory and either receiving anticonvulsants or not; all had developmental delays.

84 but no cross-reactivity was seen with other anticonvulsants or structural analogs.

85 psychotics, combinations of antidepressants, anticonvulsants, or "other") for >/=60 consecutive days

86 , which was similar to that observed for the anticonvulsants phenytoin (slowly binds to the fast-inac

87 The widely prescribed anticonvulsants phenytoin and carbamazepine are potent i

88 eceived treatment for 30 days or longer with anticonvulsants (phenytoin, phenobarbital, carbamazepine

89 Conventional anticonvulsants reduce neuronal excitability through eff

90 Alternatives to enzyme-inducing anticonvulsants should be prescribed for patients receiv

91 ng at very high rates, suggesting that these anticonvulsants should cause impaired GABAergic inhibiti

92 TCAs (SMD, -0.78 [CrI, -1.24 to -0.33]), and anticonvulsants (SMD, -0.67 [CrI, -0.97 to -0.37]) were

93 epinephrine reuptake inhibitors (SNRIs) than anticonvulsants (standardized mean difference [SMD], -0.

94 ng-term relapse prevention; the evidence for anticonvulsants such as divalproex and lamotrigine is le

95 lectroencephalographic response to GABAergic anticonvulsants such as phenobarbital and benzodiazepine

96 eclude the efficacy of widely used GABAergic anticonvulsants such as phenobarbital.

97 CBZ) and oxcarbazepine (OXC) are widely used anticonvulsants that are extensively metabolized in the

98 activity in the cortex is not suppressed by anticonvulsants that block the transmission of seizure a

99 tribute to resistance of seizure activity to anticonvulsants that increase GABAergic function, and ma

100 two of which are approved for human use, are anticonvulsants that modulate neural activity.

101 As a class of anticonvulsants, the 3,3-disubstituted 2-pyrrolidinones

102 Except for anticonvulsants, the adjusted risks for all individual c

103 des because of the increased availability of anticonvulsants, the ketogenic diet has re-emerged as a

104 yl-N'-(4-methoxynaphth-1-yl)guanidine (3) as anticonvulsants through blockade of sodium channels.

105 is to stop the seizures quickly enough with anticonvulsants to prevent brain damage.

106 In seeking broad-spectrum anticonvulsants to treat epilepsy and other neurological

107 to treatment with tricyclic antidepressants, anticonvulsants (topiramate), coenzyme Q-10, and L-carni

108 differences in sex distribution or number of anticonvulsants used between patients with bruising/blee

109 , attempted suicides, and violent deaths for anticonvulsants used in at least 100 treatment episodes

110 illness, use of antidepressants, and use of anticonvulsants versus lithium.

111 reased rate of end-stage CKD, whereas use of anticonvulsants was (1-2 prescriptions, HR = 0 [95% CI,

112 ,5-diones as potential broad-spectrum hybrid anticonvulsants was described.

113 rtication at age 8.5 years and withdrawal of anticonvulsants when he was more than 9 years old, Alex

114 nonketotic hyperglycinemia required multiple anticonvulsants, whereas patients with developmental quo

115 ribute an important component to binding for anticonvulsants, which compensates energetically for the

116 ical conditions, such as antidepressants and anticonvulsants, which were found empirically to be effe

117 compound was directed to identifying potent anticonvulsants with a long duration of action and a fav

118 tassium channels, we have docked these three anticonvulsants with residues identified by mutagenesis

119 mnolence and dizziness with TCAs, SNRIs, and anticonvulsants; xerostomia with TCAs; and peripheral ed